Yannick Allanore - Concepedia

Author

Yannick Allanore

Also Known As

Allanore, Y, Allanore, Y., Allanore, Yannick, Ariane L. Herrick, Bojana Stamenkovic, C. P. Denton, Christian Agard, Hervé Lévesque, JAVIER MARTIN, Jane Worthington

982

Publications

41.5K

Citations

H-Index

168

Concepts

All Affiliations

Hôpital Cochin Université Paris Cité Délégation Paris 5 Assistance Publique – Hôpitaux de Paris Inserm

About

Yannick Allanore is an author at Hôpital Cochin specializing in medicine, scleroderma, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	38	78	6.1K
2	Public Health	13	14	709
3	Health Sciences	5	5	248
4	Engineering	1	1	63
5	Social Sciences	1	1	27

Yannick Allanore

334

Publications

31.8K

Citations

H-Index

Page 1

	Year	Citations
2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative F.H.J. van den Hoogen, Dinesh Khanna, Jaap Fransen, Arthritis & Rheumatism	2013	3.3K
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative F.H.J. van den Hoogen, Dinesh Khanna, Jaap Fransen, Annals of the Rheumatic Diseases	2013	2.8K
Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study É. Hachulla, Virginie Gressin, Patrick Carpentier, Arthritis & Rheumatism	2005	733
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial Dinesh Khanna, Christopher P. Denton, Angelika Jahreis, The Lancet RheumatologyAutoimmune DiseaseSystemic SclerodermaSubcutaneous TocilizumabSystemic Sclerosis	2016	652
Mapping and predicting mortality from systemic sclerosis Muriel Elhaï, Christophe Meune, Marouane Boubaya, Annals of the Rheumatic Diseases	2017	642
Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry Florence Tubach, Dominique Salmon, Philippe Ravaud, Arthritis & Rheumatism	2009	628
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial Dinesh Khanna, Celia J. F. Lin, Daniel E. Furst, The Lancet Respiratory Medicine Autoimmune DiseaseSystemic SclerodermaImmunologySystemic SclerosisMultiple Sclerosis	2020	612
Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis Dinesh Khanna, Daniel E. Furst, Philip J. Clements, Journal of Scleroderma and Related Disorders RheumatologyTranslational MedicineOutcome MeasureSystemic SclerodermaClinical Trials	2017	487
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease Pierre‐Antoine Juge, Joyce Lee, Esther Ebstein, New England Journal of Medicine	2018	475
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group Jérôme Avouac, Jaap Fransen, U.A. Walker, Annals of the Rheumatic Diseases	2010	428

Page 1